DK1912979T3 - Phenyl-{3-{3-(1H-pyrrol-2-YL)-[1,2,4]oxadiazol-5-YL]piperidin-1-YL}-methanon-derivater og beslægtede forbindelser som positive allosteriske modulatorer af metabotrope glutamat-receptorer - Google Patents
Phenyl-{3-{3-(1H-pyrrol-2-YL)-[1,2,4]oxadiazol-5-YL]piperidin-1-YL}-methanon-derivater og beslægtede forbindelser som positive allosteriske modulatorer af metabotrope glutamat-receptorerInfo
- Publication number
- DK1912979T3 DK1912979T3 DK06779899.1T DK06779899T DK1912979T3 DK 1912979 T3 DK1912979 T3 DK 1912979T3 DK 06779899 T DK06779899 T DK 06779899T DK 1912979 T3 DK1912979 T3 DK 1912979T3
- Authority
- DK
- Denmark
- Prior art keywords
- metabotrope
- oxadiazol
- pyrrol
- piperidin
- phenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- -1 1H-pyrrol-2-YL Chemical class 0.000 title 2
- 102000018899 Glutamate Receptors Human genes 0.000 title 1
- 108010027915 Glutamate Receptors Proteins 0.000 title 1
- 230000003281 allosteric effect Effects 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 abstract 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000027232 peripheral nervous system disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003233 pyrroles Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Fats And Perfumes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0510141.5A GB0510141D0 (en) | 2005-05-18 | 2005-05-18 | Novel compounds B3 |
| PCT/IB2006/002047 WO2006123257A2 (en) | 2005-05-18 | 2006-05-17 | Phenyl-3-{(3-(1h-pyrrol-2-yl)-[1, 2 , 4]0xadiaz0l-5-yl]piperidin-1-yl}-methanone derivatives and related compounds as positive allosteric modulators of metabotropic glutamate receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1912979T3 true DK1912979T3 (da) | 2011-08-22 |
Family
ID=34708379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06779899.1T DK1912979T3 (da) | 2005-05-18 | 2006-05-17 | Phenyl-{3-{3-(1H-pyrrol-2-YL)-[1,2,4]oxadiazol-5-YL]piperidin-1-YL}-methanon-derivater og beslægtede forbindelser som positive allosteriske modulatorer af metabotrope glutamat-receptorer |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20090203737A1 (da) |
| EP (1) | EP1912979B1 (da) |
| JP (2) | JP2008540637A (da) |
| KR (1) | KR20080014046A (da) |
| CN (1) | CN101218234B (da) |
| AT (1) | ATE513828T1 (da) |
| AU (1) | AU2006248657B2 (da) |
| BR (1) | BRPI0610059A2 (da) |
| CA (1) | CA2608324A1 (da) |
| CY (1) | CY1111859T1 (da) |
| DK (1) | DK1912979T3 (da) |
| EA (1) | EA014081B1 (da) |
| ES (1) | ES2367663T3 (da) |
| GB (1) | GB0510141D0 (da) |
| IL (1) | IL187187A0 (da) |
| MX (1) | MX2007014403A (da) |
| NO (1) | NO20076480L (da) |
| NZ (1) | NZ564202A (da) |
| PL (1) | PL1912979T3 (da) |
| PT (1) | PT1912979E (da) |
| UA (1) | UA92494C2 (da) |
| WO (1) | WO2006123257A2 (da) |
| ZA (1) | ZA200710279B (da) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0510141D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
| GB0510140D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B2 |
| MX2007014444A (es) * | 2005-05-18 | 2008-04-21 | Addex Pharmaceuticals Sa | Derivados de oxadiazol sustituido como moduladores aloestericos positivos de los receptores de glutamato metabotropicos. |
| GB0510139D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| GB0510142D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| GB0622202D0 (en) * | 2006-11-07 | 2006-12-20 | Addex Pharmaceuticals Sa | Novel compounds |
| CN101874029A (zh) | 2007-07-13 | 2010-10-27 | 艾德克斯药品股份有限公司 | 作为代谢型谷氨酸受体调节剂的吡唑衍生物 |
| CA2697551C (en) | 2007-09-20 | 2013-03-12 | Irm Llc | Piperidine derivatives as modulators of gpr119 activity |
| AR072297A1 (es) | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
| US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| US20100317630A1 (en) * | 2009-02-04 | 2010-12-16 | Recordati Ireland Limited | Novel heterocyclic compounds as mglu5 antagonists |
| TW201035088A (en) | 2009-02-27 | 2010-10-01 | Supergen Inc | Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors |
| JP2012524798A (ja) * | 2009-04-23 | 2012-10-18 | メルク・シャープ・エンド・ドーム・コーポレイション | ２−アルキルピペリジンｍｇｌｕｒ５受容体モジュレーター |
| GB0912946D0 (en) | 2009-07-24 | 2009-09-02 | Addex Pharmaceuticals Sa | New compounds 5 |
| US8772301B2 (en) | 2009-12-18 | 2014-07-08 | Sunovion Pharmaceuticals, Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
| CN102762572A (zh) | 2010-02-01 | 2012-10-31 | 诺瓦提斯公司 | 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物 |
| CN102753527B (zh) | 2010-02-02 | 2014-12-24 | 诺华股份有限公司 | 用作crf受体拮抗剂的环己基酰胺衍生物 |
| WO2011140190A1 (en) | 2010-05-05 | 2011-11-10 | Infinity Pharmaceuticals | Tetrazolones as inhibitors of fatty acid synthase |
| UA114711C2 (uk) | 2011-05-13 | 2017-07-25 | Еррей Біофарма Інк. | Сполуки піролідинілсечовини й піролідинілтіосечовини як інгібітори кінази trka |
| CN104066729A (zh) | 2011-08-15 | 2014-09-24 | 英特穆恩公司 | 溶血磷脂酸受体拮抗剂 |
| CN106957282B (zh) | 2011-12-21 | 2019-08-30 | 诺维拉治疗公司 | B型肝炎抗病毒剂 |
| AR092270A1 (es) | 2012-08-28 | 2015-04-08 | Janssen R&D Ireland | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b |
| HRP20161613T1 (hr) | 2012-11-13 | 2017-01-13 | Array Biopharma, Inc. | Tvari bicikličke ureje, tioureje, gvanidina i cijanogvanidina korisne za liječenje boli |
| US9981959B2 (en) | 2012-11-13 | 2018-05-29 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| US9809578B2 (en) | 2012-11-13 | 2017-11-07 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors |
| US9790178B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| WO2014078331A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| WO2014078378A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| US9822118B2 (en) | 2012-11-13 | 2017-11-21 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| WO2014078328A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| EP2922844B1 (en) | 2012-11-13 | 2018-01-10 | Array Biopharma, Inc. | N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| US9790210B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| ES2628953T3 (es) | 2013-02-28 | 2017-08-04 | Janssen Sciences Ireland Uc | Sulfamoilarilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis B |
| WO2014165128A2 (en) | 2013-03-12 | 2014-10-09 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
| MX353412B (es) | 2013-04-03 | 2018-01-10 | Janssen Sciences Ireland Uc | Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| PL3024819T3 (pl) | 2013-07-25 | 2018-08-31 | Janssen Sciences Ireland Uc | Pochodne piroloamidowe podstawione glioksamidem i ich zastosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B |
| SG11201602748XA (en) | 2013-10-23 | 2016-05-30 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| KR20160128305A (ko) | 2014-02-05 | 2016-11-07 | 노비라 테라퓨틱스, 인코포레이티드 | Hbv 감염의 치료를 위한 병용 요법 |
| ES2705401T3 (es) | 2014-02-06 | 2019-03-25 | Janssen Sciences Ireland Uc | Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la Hepatitis B |
| US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
| RU2719489C2 (ru) | 2014-05-15 | 2020-04-17 | Эррэй Биофарма Инк. | 1-((3S,4R)-4-(3-ФТОРФЕНИЛ)-1-(2-МЕТОКСИЭТИЛ)ПИРРОЛИДИН-3-ИЛ)-3-(4-МЕТИЛ-3-(2-МЕТИЛПИРИМИДИН-5-ИЛ)-1-ФЕНИЛ-1Н-ПИРАЗОЛ-5-ИЛ)МОЧЕВИНА В КАЧЕСТВЕ ИНГИБИТОРА TrkA КИНАЗЫ |
| EP3271019A1 (en) | 2015-03-19 | 2018-01-24 | Novira Therapeutics Inc. | Azocane and azonane derivatives and methods of treating hepatitis b infections |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| JP6845231B2 (ja) | 2015-09-29 | 2021-03-17 | ノヴィラ・セラピューティクス・インコーポレイテッド | Ｂ型肝炎抗ウイルス薬の結晶形態 |
| KR20180129943A (ko) | 2016-04-15 | 2018-12-05 | 노비라 테라퓨틱스, 인코포레이티드 | 캡시드 조립 억제제를 포함하는 배합물 및 방법 |
| MY196582A (en) | 2018-02-13 | 2023-04-19 | Gilead Sciences Inc | PD-1/PD-L1 Inhibitors |
| EP3765011A1 (en) | 2018-03-14 | 2021-01-20 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
| WO2019204609A1 (en) | 2018-04-19 | 2019-10-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| PT3820572T (pt) | 2018-07-13 | 2023-11-10 | Gilead Sciences Inc | Inibidores pd-1/pd-l1 |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| EP3870566A1 (en) | 2018-10-24 | 2021-09-01 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| US20220089581A1 (en) * | 2019-01-25 | 2022-03-24 | University Of Virginia Patent Foundation | Inhibitors of spinster homolog 2 (spns2) for use in therapy |
| MA55020A (fr) | 2019-02-22 | 2021-12-29 | Janssen Sciences Ireland Unlimited Co | Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b |
| AR119732A1 (es) | 2019-05-06 | 2022-01-05 | Janssen Sciences Ireland Unlimited Co | Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb |
| LT4069691T (lt) | 2019-12-06 | 2024-12-10 | Vertex Pharmaceuticals Incorporated | Pakeistieji tetrahidrofuranai kaip natrio kanalų moduliatoriai |
| EP4085056A1 (en) | 2020-01-03 | 2022-11-09 | Berg LLC | Polycyclic amides as ube2k modulators for treating cancer |
| WO2022069953A1 (en) * | 2020-09-29 | 2022-04-07 | Ranjith Siddaraj | Synthesis and characterization of (s)-3-(5- fluoropyridin-2-yl)-5-(piperidin-3-yl)-l,2,4-oxadiazole derivatives and their secretory phospholipase a2 (spla2) inhibitor activity |
| DK4347031T3 (da) | 2021-06-04 | 2025-12-01 | Vertex Pharma | N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler |
| WO2024059207A2 (en) * | 2022-09-15 | 2024-03-21 | Vanderbilt University | Pyrazoloether analogs as mglu5 negative allosteric modulators and methods of making and using the same |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3509153A (en) * | 1967-03-24 | 1970-04-28 | Miles Lab | 5-phenyl (or 5-phenylalkyl)-2-(omega-(4-phenyl-1-piperazinyl)alkyl)tetrazoles |
| US3991064A (en) * | 1975-01-17 | 1976-11-09 | Warner-Lambert Company | Benzonaphthyridines |
| US3966748A (en) * | 1975-05-08 | 1976-06-29 | American Cyanamid Company | Para-fluorophenyl-N-heterocyclic substituted butanes |
| US5338969A (en) * | 1991-06-27 | 1994-08-16 | Texas Instruments, Incorporated | Unerasable programmable read-only memory |
| US6846839B1 (en) * | 1995-06-07 | 2005-01-25 | Sugen, Inc. | Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis |
| GB9603755D0 (en) * | 1996-02-22 | 1996-04-24 | Pfizer Ltd | Therapeutic agents |
| US6437146B1 (en) * | 1998-09-25 | 2002-08-20 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compounds as prostaglandin e2 agonists or antagonists |
| US7217714B1 (en) * | 1998-12-23 | 2007-05-15 | Agouron Pharmaceuticals, Inc. | CCR5 modulators |
| WO2000066578A1 (en) * | 1999-04-30 | 2000-11-09 | Pfizer Products Inc. | Compounds for the treatment of obesity |
| SK8452002A3 (en) * | 1999-12-16 | 2002-11-06 | Schering Corp | Substituted 4-(phenyl or pyridyl)imidazole derivatives, pharmaceutical composition comprising the same and use thereof |
| AR033517A1 (es) * | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| NZ522773A (en) | 2000-06-12 | 2005-06-24 | Eisai Co Ltd | 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof |
| EP1289955B1 (en) * | 2000-06-16 | 2005-04-13 | Smithkline Beecham Plc | Piperidines for use as orexin receptor antagonists |
| US6894063B2 (en) * | 2000-09-14 | 2005-05-17 | Schering Corporation | Substituted urea neuropeptide Y Y5 Receptor antagonists |
| US6946476B2 (en) * | 2000-12-21 | 2005-09-20 | Schering Corporation | Heteroaryl urea neuropeptide Y Y5 receptor antagonists |
| NZ531637A (en) * | 2001-09-21 | 2005-12-23 | Mitsubishi Pharma Corp | 3-substituted-4-pyrimidone derivatives as tau protein kinase 1 inhibitor |
| WO2003037888A1 (en) * | 2001-09-21 | 2003-05-08 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
| AU2002341921B2 (en) * | 2001-10-04 | 2007-05-31 | Merck Sharp & Dohme Corp. | Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| US20050014942A1 (en) * | 2001-10-30 | 2005-01-20 | Yasufumi Maruyama | Amide derivatives and drugs |
| US6806279B2 (en) * | 2001-12-17 | 2004-10-19 | Sunesis Pharmaceuticals, Inc. | Small-molecule inhibitors of interleukin-2 |
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| WO2003093236A1 (en) | 2002-05-02 | 2003-11-13 | Euro-Celtique, S.A. | 1-(pyrid-2-yl)-piperazine compounds as metabotropic glutamate receptor inhibitor |
| WO2003093297A2 (en) | 2002-05-03 | 2003-11-13 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| MXPA05001590A (es) * | 2002-08-09 | 2005-05-23 | Astrazeneca Ab | Compuestos que tienen actividad en los receptores metabotropicos de glutamato. |
| US20040127501A1 (en) * | 2002-09-24 | 2004-07-01 | Zhengming Chen | Therapeutic agents useful for treating pain |
| CN100439337C (zh) * | 2002-11-26 | 2008-12-03 | 辉瑞产品公司 | 作为ppar活化剂的苯基取代的哌啶化合物 |
| US7582635B2 (en) | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
| GEP20094675B (en) * | 2003-07-24 | 2009-05-10 | Euro Celtique Sa | Heteroaryl- tetra-hydropiperidyl compounds useful for treating or preventing pain |
| WO2005021548A2 (en) * | 2003-08-25 | 2005-03-10 | Adenosine Therapeutics, Llc | Substituted 8-heteroaryl xanthines |
| GB0325956D0 (en) * | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| FR2865733B1 (fr) * | 2004-02-04 | 2007-10-12 | Merck Sante Sas | Derives de thiazolylimidazole, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en medecine |
| RU2353362C2 (ru) | 2004-05-25 | 2009-04-27 | Пфайзер Продактс Инк. | Новое применение |
| ATE499356T1 (de) | 2004-09-29 | 2011-03-15 | Mitsubishi Tanabe Pharma Corp | 6-(pyridinyl)-4-pyrimidonderivate als inhibitoren der tau-proteinkinase-1 |
| JP2008516962A (ja) | 2004-10-15 | 2008-05-22 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 血管傷害を治療する方法 |
| GB0510143D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| WO2006048771A1 (en) | 2004-11-04 | 2006-05-11 | Addex Pharmaceuticals Sa | Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| ATE542817T1 (de) * | 2004-11-10 | 2012-02-15 | Ono Pharmaceutical Co | Stickstoffhaltige heterocyclische verbindung und deren pharmazeutische verwendung |
| CA2589084A1 (en) | 2004-12-15 | 2006-06-22 | Merck & Co., Inc. | Inhibitors of akt activity |
| GB0510141D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
| GB0510140D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B2 |
| GB0510142D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| GB0510139D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| MX2007014444A (es) * | 2005-05-18 | 2008-04-21 | Addex Pharmaceuticals Sa | Derivados de oxadiazol sustituido como moduladores aloestericos positivos de los receptores de glutamato metabotropicos. |
| GB0622202D0 (en) * | 2006-11-07 | 2006-12-20 | Addex Pharmaceuticals Sa | Novel compounds |
-
2005
- 2005-05-18 GB GBGB0510141.5A patent/GB0510141D0/en not_active Ceased
-
2006
- 2006-05-17 EP EP06779899A patent/EP1912979B1/en not_active Not-in-force
- 2006-05-17 KR KR1020077029429A patent/KR20080014046A/ko not_active Ceased
- 2006-05-17 AU AU2006248657A patent/AU2006248657B2/en not_active Expired - Fee Related
- 2006-05-17 CN CN2006800251802A patent/CN101218234B/zh not_active Expired - Fee Related
- 2006-05-17 EA EA200702470A patent/EA014081B1/ru not_active IP Right Cessation
- 2006-05-17 PT PT06779899T patent/PT1912979E/pt unknown
- 2006-05-17 WO PCT/IB2006/002047 patent/WO2006123257A2/en not_active Ceased
- 2006-05-17 NZ NZ564202A patent/NZ564202A/en not_active IP Right Cessation
- 2006-05-17 CA CA002608324A patent/CA2608324A1/en not_active Abandoned
- 2006-05-17 JP JP2008511823A patent/JP2008540637A/ja active Pending
- 2006-05-17 BR BRPI0610059-7A patent/BRPI0610059A2/pt not_active IP Right Cessation
- 2006-05-17 DK DK06779899.1T patent/DK1912979T3/da active
- 2006-05-17 UA UAA200714061A patent/UA92494C2/ru unknown
- 2006-05-17 ES ES06779899T patent/ES2367663T3/es active Active
- 2006-05-17 MX MX2007014403A patent/MX2007014403A/es active IP Right Grant
- 2006-05-17 PL PL06779899T patent/PL1912979T3/pl unknown
- 2006-05-17 AT AT06779899T patent/ATE513828T1/de active
- 2006-05-17 US US11/920,490 patent/US20090203737A1/en not_active Abandoned
-
2007
- 2007-11-06 IL IL187187A patent/IL187187A0/en unknown
- 2007-11-28 ZA ZA200710279A patent/ZA200710279B/xx unknown
- 2007-12-17 NO NO20076480A patent/NO20076480L/no not_active Application Discontinuation
-
2011
- 2011-09-22 CY CY20111100921T patent/CY1111859T1/el unknown
-
2012
- 2012-05-24 JP JP2012118718A patent/JP2012184254A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CY1111859T1 (el) | 2015-11-04 |
| AU2006248657A1 (en) | 2006-11-23 |
| US20090203737A1 (en) | 2009-08-13 |
| IL187187A0 (en) | 2008-02-09 |
| EA014081B1 (ru) | 2010-08-30 |
| NO20076480L (no) | 2008-01-28 |
| WO2006123257A8 (en) | 2007-03-15 |
| HK1112909A1 (en) | 2008-09-19 |
| EP1912979A2 (en) | 2008-04-23 |
| ATE513828T1 (de) | 2011-07-15 |
| AU2006248657B2 (en) | 2012-07-19 |
| ZA200710279B (en) | 2009-03-25 |
| PT1912979E (pt) | 2011-08-22 |
| KR20080014046A (ko) | 2008-02-13 |
| MX2007014403A (es) | 2008-04-21 |
| CA2608324A1 (en) | 2006-11-23 |
| WO2006123257A2 (en) | 2006-11-23 |
| JP2012184254A (ja) | 2012-09-27 |
| EA200702470A1 (ru) | 2008-06-30 |
| WO2006123257A3 (en) | 2007-05-03 |
| BRPI0610059A2 (pt) | 2010-05-25 |
| CN101218234A (zh) | 2008-07-09 |
| GB0510141D0 (en) | 2005-06-22 |
| UA92494C2 (ru) | 2010-11-10 |
| NZ564202A (en) | 2011-04-29 |
| EP1912979B1 (en) | 2011-06-22 |
| ES2367663T3 (es) | 2011-11-07 |
| CN101218234B (zh) | 2011-12-14 |
| PL1912979T3 (pl) | 2011-11-30 |
| JP2008540637A (ja) | 2008-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1912979T3 (da) | Phenyl-{3-{3-(1H-pyrrol-2-YL)-[1,2,4]oxadiazol-5-YL]piperidin-1-YL}-methanon-derivater og beslægtede forbindelser som positive allosteriske modulatorer af metabotrope glutamat-receptorer | |
| NO20076479L (no) | Nye oksadiazolderivater og anvendelse derav som positive allosteriske metabotropiske modulatorer av glutamatreseptorer | |
| EA200702471A1 (ru) | Новые гетероциклические соединения в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов | |
| NO20076478L (no) | Substituerte oksadiazolderivater som positive allosteriske modulatorer av metabotrope glutamatreseptorer | |
| DK1685105T3 (da) | Allosteriske modulatorer af metabotropiske glutamatreceptorer | |
| NO20082136L (no) | 1,5-substituerte indol-2-yl-amidderivater | |
| ATE493397T1 (de) | Neuartige tetrazolderivate als positive allosterische modulatoren von metabotropen glutamatrezeptoren | |
| PE20080830A1 (es) | Compuestos derivados de sulfonilo que modulan el receptor cb2 | |
| MXPA06014721A (es) | Derivados de alquinilo como moduladores de los receptores de glutamato metabotropico. | |
| NO20075626L (no) | Heteroarylbenzamid-derivater for anvendelse som GLK-aktivatorer i behandling av diabetes | |
| NO20071642L (no) | N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger | |
| NO20082214L (no) | 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer | |
| DE502005008416D1 (de) | Verwendung von substituierten 2-thio-3,5-dicyano-4-phenyl-6-aminopyridinen bei der behandlung von übelkeit und erbrechen | |
| ATE467632T1 (de) | Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors | |
| DK1893589T3 (da) | Substituerede N-benzo[d]isoxazol-3-yl-amin-derivater som inhibitorer af mGluR5-, serotonin-(5-HT) og noradrenalinreceptorer og deres anvendelse til fremstilling af lægemidler | |
| ATE473968T1 (de) | Cycloalkylidinverbindungen als selektive modulatoren des östrogenrezeptors | |
| ATE479691T1 (de) | 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3- modulatoren | |
| ATE502947T1 (de) | 4,5,6,7-tetrahydrothienoä3,2-cüpyridinderivate als h3-modulatoren | |
| HK1110852A (en) | Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors | |
| HK1110076A (en) | Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | |
| UA92495C2 (ru) | Замещенные производные оксадиазола как положительные аллостерические модуляторы метаботропных глутаматных рецепторов | |
| HK1111148A (en) | Novel heterocyclic compounds as positive allosteric modulators of metabotropic glutamate receptors |